CCIA
OVID icon

Campbell & Co Investment Adviser’s Ovid Therapeutics OVID Stock Holding History

Campbell & Co Investment Adviser’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,700
Closed -$54K – 720
2021
Q2 		$54K Buy
+13,700
New +$54.1K 0.02% 505

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Campbell & Co Investment Adviser's OVID Position: Q3 2021 in Review

Campbell & Co Investment Adviser sold out of Ovid Therapeutics (OVID) in Q3 2021, closing a stake of 13,700 shares — an estimated $54K sold.

Campbell & Co Investment Adviser first reported a position in OVID in Q2 2021 and held it in 1 quarter. The position peaked at $54K in Q2 2021. 72 funds tracked by Wall St. Rank hold OVID as of Q3 2021.

  • Campbell & Co Investment Adviser reported no remaining Ovid Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 13,700 Ovid Therapeutics shares in Q3 2021, an estimated $54K.
  • Campbell & Co Investment Adviser first reported a position in Ovid Therapeutics in Q2 2021 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Ovid Therapeutics position peaked at $54K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2021.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2021, filed 10 Nov 2021.